Holen Sie sich die Stockscreener-App
104.10
2.02%
-2.15
Schlusskurs vom Vortag:
$106.25
Offen:
$104.73
24-Stunden-Volumen:
425.88K
Relative Volume:
0.62
Marktkapitalisierung:
$5.51B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-15.94
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-6.98%
1M Leistung:
-1.49%
6M Leistung:
+15.54%
1J Leistung:
+43.57%
1-Tages-Spanne:
$103.71
$106.03
1-Wochen-Bereich:
$103.71
$112.98
52-Wochen-Spanne:
$71.15
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
104.10 | 5.51B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com
Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Rhumbline Advisers - MarketBeat
William Blair Analysts Reduce Earnings Estimates for AXSM - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by GAMMA Investing LLC - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat
Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat
Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus
Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN
Royal Bank of Canada Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus
Assenagon Asset Management S.A. Has $73.18 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - marketscreener.com
Cantor Fitzgerald Predicts AXSM FY2026 Earnings - MarketBeat
Axsome fell after FDA refuses to review AXS-14 application - MSN
Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 - Toronto Star
Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st
Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World
Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada
Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa
Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga
Axsome Therapeutics (AXSM) Faces Setback After FDA Declines AXS-14 Review - GuruFocus
Axsome Therapeutics Shareholders Approve Key Proposals at Meeting - TipRanks
Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - marketscreener.com
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required - Benzinga
Axsome Therapeutics (AXSM) Price Target Adjusted by Needham Anal - GuruFocus
Axsome shares fall after FDA issues Refusal to File letter By Investing.com - Investing.com South Africa
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail's Skeptical On Likelihood Of Year-End Profitability - MENAFN.com
Axsome shares fall after FDA issues Refusal to File letter - Investing.com
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews - Benzinga
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability - MSN
Axsome Therapeutics (AXSM) Faces FDA Setback for Fibromyalgia Drug | AXSM Stock News - GuruFocus
Axsome Therapeutics Receives FDA's Refuse-to-File Letter for AXS-14 New Drug Application - marketscreener.com
Axsome slips as FDA rejects fibromyalgia drug application, forcing new trial - TradingView
Axsome Therapeutics Provides Update On The New Drug Application For Axs-14 For Fibromyalgia - marketscreener.com
Axsome’s fibromyalgia drug application hits FDA roadblock - Investing.com
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia - Yahoo Finance
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,928 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Jun 09 '25 |
Sale |
110.44 |
25,000 |
2,761,000 |
5,783 |
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):